Manufacturing News of Note—Aurobindo gets 2 483s; Catalent to make BeiGene drug

stocks
(Pixabay)

> The FDA recently posted two Form 483s issued to India’s Aurobindo in October; one for a sterile facility and one for an API facility. 

> CDMO Catalent has been tapped by China's BeiGene, to manufacture its immuno-oncology drug Brukinsa. Release 

> South Korea and Singapore have signed an agreement to work together and share information GMP inspections. Story 

> Ingredient supplier Barentz says that private equity firm Cinven has made an investment that will allow it to expand. Story